Innate immune responses are critical in the process of immune surveillance, with natural killer (NK) and NK1.1
+ T (NKT) cells being among the main mediators of early host responses. The role of NK cells in these processes has been the subject of intensive investigation, and it is clear that they play a crucial role as effectors in tumor control (
38,
41,
46) as well as in limiting the spread of viral infections (
4,
5,
42). In particular, infection of mice by the herpesvirus murine cytomegalovirus (MCMV) has proven to be one of the best systems for evaluating the role of NK cells following a viral challenge (
29,
43). In contrast, NKT cells have been shown to play a central role in early innate responses to tumors (
35,
37), but their relevance in response to challenges with viral pathogens is still largely unclear (
5). Here, we have examined the relevance of classical, T-cell receptor (TCR)-restricted NKT cells in controlling MCMV infection. Because of the similarity in structure and biology between MCMV and human cytomegalovirus, the former provides a unique model of human disease and, importantly, it permits the study of in vivo infection in the natural host (
1).
Classical murine NKT cells are a specialized subset of T lymphocytes that express a number of NK cell markers, including NK1.1 (
3,
14), together with a restricted TCR repertoire, consisting of a single invariant TCR α chain encoded by Vα14Jα281 in association with a Vβ8.2, Vβ7, or Vβ2 TCR β chain. The resultant semi-invariant TCRαβ is specific for CD1d, a nonclassical class I molecule (
3) and recognizes glycolipid antigens, the nature of which is currently unclear. A marine sponge-derived glycosphingolipid, α-galactosylceramide (α-GalCer), has been identified as a ligand that specifically binds the semi-invariant TCR of NKT cells in association with CD1d (
8,
21). Following the association of the α-GalCer/CD1d complex with the Vα14 TCR, NKT cells become activated (
8,
21), rapidly release immunoregulatory cytokines, such as gamma interferon (IFN-γ) or interleukin 4 (IL-4), and increase their cytotoxic capacity (
3,
21,
22).
Rapid release of cytokines by NKT cells suggests their role in the regulation of immune responses and highlights their potential as targets for immunotherapy. Indeed, α-GalCer-stimulated NKT cells have been shown to drive immune responses with both Th1 and Th2 biases. For example, repeated α-GalCer administration can enhance Th2-mediated immune responses (
9,
24,
33), which have been shown to protect against experimentally induced Th1-type colitis (
31) and type I diabetes (
17,
32). Conversely, α-GalCer has also been shown to protect against malaria (
15) and to suppress the ability of the B16 melanoma to form liver and lung metastases by a Th1- and IFN-γ-dependent mechanism (
22,
27,
36,
45). Importantly, it is now appreciated that the antitumor effects of α-GalCer are mediated in a collaborative manner by both NK and NKT cells (
26,
34,
36).
The induction of antitumor immune responses following α-GalCer therapy has been proposed to occur in a defined sequence of events (
35). Briefly, production of IFN-γ by α-GalCer-stimulated NKT cells induces IL-12 production by CD11c
+ dendritic cells (DC) in a CD40/CD40L-dependent manner, thus establishing a positive feedback loop for IFN-γ production (
23,
44). IFN-γ and IL-12, resulting from activation of NKT cells, then selectively induce NK cell proliferation, IFN-γ secretion, and cytotoxicity (
12,
35). NKT cells activated by α-GalCer can subsequently promote bystander activation of NK cells, B cells, CD4
+ T cells, CD8
+ cytotoxic T lymphocytes, and DC (
9,
10,
12,
23,
24,
28).
The relevance of α-GalCer-activated classical NKT cells in the control of herpesvirus infections is unknown. Here, we have utilized the MCMV model of viral infection to determine the relevance of NKT cells in the early immune responses that limit the spread of this herpesvirus infection in visceral organs. The cytotoxic function of NK cells is known to control MCMV replication in visceral organs during acute-phase infection (
7,
43) and limit viral spread and replication prior to the development of adaptive CD8
+-cytotoxic-T-lymphocyte responses which resolve productive virus infection (
25,
30). In this report, we show that although NKT cells do not play a role in the natural control of MCMV infection, their activation, following α-GalCer therapy, results in improved viral clearance through the activation of bystander NK cells.
DISCUSSION
The contribution of NK cells in innate immune responses to viral infections is well established. In contrast, the involvement of NKT cells in viral immune surveillance remains poorly understood (
5). In this study, we investigated the relevance of NKT cells during infection with the herpesvirus MCMV. The role of NKT cells was defined both in the context of a natural infection and after activation with α-GalCer. Treatment of mice with α-GalCer induced a significant antiviral response resulting in decreased virus titers in the visceral organs of MCMV-susceptible BALB/c WT mice. Similar results were obtained in B6 WT mice. Although normally resistant to MCMV infection, B6 WT mice show susceptibility to escalating doses of virus (
2). At a dose of 10
5 PFU, which caused pathogenesis in B6 WT vehicle-treated mice, B6 WT mice receiving α-GalCer demonstrated reduced viral replication, with lower titers in both the spleen and liver, similar to the effects observed with BALB/c WT mice.
The effects of α-GalCer therapy are normally mediated by a potent and selective activation of NKT cells via association of the α-GalCer/CD1d complex with the Vα14 TCR (
6,
8,
21). In MCMV infection, we have shown that NKT cells are necessary to induce the α-GalCer-mediated antiviral therapy, since the effects of α-GalCer were abolished in NKT-cell-deficient B6.Jα281
−/− mice. Importantly, although activation of NKT cells results in improved viral clearance, these cells do not play a major role in controlling the early acute phase of natural infection with MCMV. Indeed, at early times postinfection, NKT-cell-deficient B6.Jα281
−/− mice did not show increased susceptibility to MCMV, since viral replication in the visceral organs of these mice was equivalent to that observed in B6 WT mice. Similarly, NKT cells have been shown to be dispensable for the control of lymphocytic choriomeningitis virus infection (
39). Although NKT cells do not appear to play a major role in restricting MCMV replication during the acute stage of infection, virus titers were transiently and slightly increased (<1.0 log) in the livers of B6.Jα281
−/− mice 10 days after infection, suggesting that NKT cells may play a role in helping to activate adaptive immune responses that control viral replication during the later stages of acute-phase infection. This conclusion was corroborated by the finding that the effects observed in B6.Jα281
−/− mice at day 10 p.i. were transient, with equivalent virus titers in B6.Jα281
−/− and B6 WT mice by day 12 p.i.
Previous studies have reported on the antiviral effects of α-GalCer-activated NKT cells, with improved viral clearance or prevention of virus-induced disease described for hepatitis B virus (
20), diabetogenic encephalomyocarditis virus (
13), and respiratory syncytial virus (
18). In the case of diabetogenic encephalomyocarditis virus (
13) and respiratory syncytial virus (
18) infections, the therapeutic effects of α-GalCer were accompanied by the demonstration that NKT cells also play a critical role in viral clearance without α-GalCer activation. Although it is not possible to conclusively ascribe the reported effects directly to classical NKT cells, as the studies were undertaken in CD1d
−/− mice, it appears that there may be differences in the role played by NKT cells and α-GalCer-activated NKT cells in different viral infections. The studies reported here may be more analogous to those of Kakimi and colleagues, which demonstrated that the α-GalCer-induced inhibition of hepatitis B virus replication was principally mediated by the rapid induction of IFN-α/β and IFN-γ in the liver (
20).
Thus, having shown that NKT cells are dispensable for the control of MCMV replication during a natural infection but essential for the antiviral efficacy of α-GalCer therapy, we wanted to establish whether the observed antiviral response was mediated directly through NKT cells or indirectly through activation of other immune effectors. It is known that activated NKT cells exhibit increased perforin-mediated cytotoxicity against tumor cell lines in vitro (
10,
12) while also rapidly releasing immunoregulatory cytokines such as IL-4 and IFN-γ (
3). Cytokines produced by activated NKT cells can in turn trigger bystander activation of NK cells, which involves proliferation, further IFN-γ production, and cytotoxicity (
10,
12).
Depletion of NK cells prior to α-GalCer therapy confirmed the involvement of these effectors in the antiviral response induced by α-GalCer, with the efficacy of the therapy almost completely abolished in mice depleted of NK cells but possessing an intact NKT cell population. Having shown that the therapeutic effects of α-GalCer in MCMV infection were mediated by the activation of NK cells, we further examined the involvement of specific effector mechanisms, namely perforin and IFN-γ, in the antiviral response by utilizing gene-targeted mice. These studies demonstrated that the α-GalCer-induced antiviral response was dependent upon both perforin-mediated cytotoxicity and IFN-γ release, as mice deficient for one or both of these molecular effector systems were unable to mount a complete α-GalCer-induced antiviral response.
Recent studies in a B16 melanoma metastasis model demonstrated that the antitumor activity of α-GalCer requires the sequential production of IFN-γ by both NKT and NK cells, but it occurs independently of perforin release (
36). This contrasts with our present findings, which clearly demonstrate that perforin is the major contributor to the α-GalCer-induced antiviral response. Although treatment of BALB/c.IFN-γ
−/− mice with α-GalCer demonstrated that the production of IFN-γ was integral to the α-GalCer-mediated antiviral effect in the spleen, the available data cannot distinguish between the relative importance of IFN-γ produced by NKT cells and NK cells. The present studies have revealed that activated NKT cells are key mediators of the antiviral effects of α-GalCer, with NK cells, IFN-γ, and perforin all playing crucial roles. Interestingly, although it has been postulated that IFN-γ is the most important anti-MCMV mechanism in the liver (
43), α-GalCer still showed an antiviral effect in these organs in IFN-γ-deficient mice. In contrast, α-GalCer therapy did not reduce viral replication in the livers of perforin-deficient mice, suggesting that perforin plays a crucial antiviral role at this site in α-GalCer-treated mice.
Activation of NKT cells by α-GalCer can lead to both IFN-γ and IL-4 secretion (
9,
24,
33). IL-4 is involved in the induction of a Th2-mediated humoral immune response, which does not play a role in the clearance of MCMV infection (
19). In BALB/c.IFN-γ
−/− mice, α-GalCer therapy had detrimental effects in the liver and lung at day 6 postinfection. Due to the targeted deletion of the IFN-γ gene in these mice, α-GalCer-stimulated NKT cells only secrete IL-4. Consequently, in these animals the balance of the immune response induced by activated NKT cells will be biased towards the Th2 pathway, resulting in less-efficient clearance of MCMV, as observed.
It is important to note that our previous studies on the effects of α-GalCer in mediating tumor suppression, together with our present analysis of α-GalCer antiviral activity, have revealed that activated NKT cells can regulate different effector immune responses. Thus, the antitumor effects of α-GalCer are dependent on NK cells and IFN-γ, whereas the α-GalCer antiviral activity requires NK cells, IFN-γ, and perforin. These differences are most likely due to differences in the key factors associated with tumor suppression versus viral clearance. Thus, a requirement for perforin-mediated cytotoxicity may be unnecessary for tumor suppression when the antiangiogenic effects of IFN-γ alone may be sufficient to prevent tumor growth and metastasis (
40). In contrast, perforin is likely to be essential in mediating the α-GalCer antiviral effects due to a requirement for direct cytolysis of virus-infected targets. Consistent with this hypothesis is the finding that the antiviral response induced by α-GalCer appears to be most potent during acute-phase MCMV infection, controlling virus replication most effectively in the spleen and liver. In both these organs, the early control of MCMV infection is highly reliant on innate effector mechanisms (
7,
43). Thus, in α-GalCer therapy, the timing of the antiviral response elicited and the organs in which it occurs concur with our conclusion that the therapy specifically and potently enhances innate immune responses mediated principally by activated NK cells.
In this report we have provided the first evidence that, although TCR Vα14Jα281 NKT cells do not play a critical role in restricting early acute-phase natural infection with MCMV, activating them with α-GalCer induces a potent and specific antiviral response. We have shown that the antiviral response elicited by α-GalCer is dependent on Vα14Jα281 NKT cells, that the effectors are activated NK cells, and that both perforin and IFN-γ are critical molecular effector mechanisms. These studies have not only elucidated the role of different innate immune effectors in viral immune surveillance, but they provide the basis for the design of targeted antiviral therapies.